Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced it is evaluating strategic acquisitions that could generate approximately $100 million in combined annual revenue if completed. The Warren, N.J.-based company said the initiatives include a previously announced evaluation of a contract research organization and additional acquisition opportunities.

The potential acquisitions are part of Tevogen's strategy to create a financially self-sufficient healthcare enterprise comprising its biotechnology arm Tevogen Bio, technology arm Tevogen.AI, and a proposed healthcare services division that may include management services and contract research operations.

"Capital discipline and preserving the integrity of our capital structure are core priorities for us," said Ryan Saadi, the company's founder and CEO. "Our strategic objective is to build a financially self-sufficient healthcare enterprise with the financial strength to support operations, advance growth initiatives, and create long-term value through revenue generation."

Tevogen stated that any capital allocation decisions will be guided by strategic fit, long-term value creation, and disciplined stewardship of its capital structure. The proposed transactions remain subject to completion of due diligence, negotiation of definitive documentation, required approvals, and customary closing conditions.

The company noted there is no assurance that any transaction will be completed. Tevogen operates as a healthcare enterprise focused on artificial intelligence and precision T cell therapy platforms, with its biotechnology division having completed a proof-of-concept clinical trial for genetically unmodified allogeneic T cells.